DTC Advertising Ban Maintained in Europe - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

DTC Advertising Ban Maintained in Europe


ePT--the Electronic Newsletter of Pharmaceutical Technology

The European Commission (EC) has adopted revised proposals clarifying the information that industry can supply to the public on prescription-only medicines, while maintaining a strict ban on direct-to-consumer advertising.

Only certain information will be allowed to be communicated, including information on the label and packaging leaflets, pricing information, instructions for use, and information on clinical trials. Channels of communication will also be strictly limited to media such as officially registered internet websites and printed information made available when specifically requested by members of the public. Dissemination in general print media, radio and television will not be permitted.

In addition, the information will have to fulfill certain quality criteria. The information must be unbiased, evidence based and factually correct, understandable, and must meet the needs and expectations of patients. Information that has not previously been approved will need to be verified by competent authorities prior to dissemination.

In a statement, John Dalli, European commissioner for health and consumer policy, said: "The revised proposals put rights, interests and safety of patients first. They oblige industry to provide certain key information to patients and set clear rules for additional, voluntary information on prescription medicines. In addition, they further strengthen the control of authorized medicines."

The EC’s first proposal was released in 2008 as part of the ‘Pharmaceutical Package’, but was amended during a vote in 2010 of MEPs of the European Parliament’s Health Committee. According to a statement of the European Public Health Alliance (EPHA), the previous proposal was “just a disguised way of giving pharmaceutical companies enough flexibility to promote their products directly to the public, in order to boost the sector’s growth.”

However, the latest proposal seems to have alleviated this concern as it has been welcomed by EPHA and the European Federation of Pharmaceutical Industries and Associations.

“EPHA welcomes the new tone of the proposal which has taken the public health perspective on board. We congratulate Commissioner Dalli for producing a revised version of the proposal,” said Monika Kosinska, secretary general of EPHA, in the EPHA statement.

According to a statement from the EC, patients are taking increased interest in the medicines they take and want more of a say in how they are treated. “At the same time, patients are confronted with a growing volume of information from various sources and often find it difficult to identify reliable information about medicines,” said the statement. “The increased use of the internet over recent years makes the need for clarity even more important. Online information on medicines must be accurate and reliable.”

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
29%
Breakthrough designations
10%
Protecting the supply chain
43%
Expedited reviews of drug submissions
10%
More stakeholder involvement
10%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here